Publications

1. GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)

   The National Health Care Institute has completed its assessment whether ozanimod (Zeposia®) for the treatment of adult patients ...

   Report | 28-10-2020

2. GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia

   The National Health Care Institute has completed its assessment whether amisulpride (Aktiprol®) can be included in the GVS. ...

   Report | 21-10-2020

3. Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder

   The National Health Care Institute has completed its assessment whether esketamine nasal spray (Spravato®) can be included in the ...

   Report | 30-09-2020

4. Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage

   The National Health Care Institute has completed its assessment whether trastuzumab-emtansine (Kadcyla®) can be included in the ...

   Report | 24-09-2020

5. Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients

   The National Health Care Institute has completed its assessment whether Indacaterol/glycopyrronium/mometasone (Enerzair® ...

   Report | 24-09-2020

6. Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older

   The National Health Care Institute has completed its assessment whether indacaterol acetate/mometasone furoate (Atectura® ...

   Report | 24-09-2020

7. Osimertinib (Tagrisso®) for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with an epidermal growth factor receptor (EGFR) mutation (reassessment)

   The Minister of Medical Care has requested the National Health Care Institute to reassess whether osimertinib (Tagrisso®) for the ...

   Report | 21-09-2020

8. Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma

   The National Health Care Institute has completed its assessment whether avelumab (Bavencio®) in combination with axitinib can be ...

   Report | 21-09-2020

9. GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis

   The National Health Care Institute completed its assessment whether an extension is possible of the conditions of List 2 of the ...

   Report | 17-08-2020

10. Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease

    The National Health Care Institute has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult ...

    Report | 03-07-2020